Session » Infection-related Rheumatic Disease Poster

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1219

Antibiotic Resistance Trends Among Bacteria Causing Septic Arthritis at One Medical Center between 2002-2016

9:00AM-11:00AM: Abstract Number: 1229

Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1226

Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1240

Foot Osteomyelitis in Inflammatory Rheumatic Diseases: A Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 1224

High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment

9:00AM-11:00AM: Abstract Number: 1234

Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors

9:00AM-11:00AM: Abstract Number: 1227

Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1230

Invasive Fungal Infection with Cryptococcal Meningitis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1235

Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids

9:00AM-11:00AM: Abstract Number: 1239

Organisms Associated with Prosthetic Joint Septic Arthritis over the Past Two Decades: Data from a Single Tertiary Medical Center Located in the Northeastern United States

9:00AM-11:00AM: Abstract Number: 1236

Peripheral-Blood B-Cell Subset Disturbances in Whipple’s Disease

9:00AM-11:00AM: Abstract Number: 1231

Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS

9:00AM-11:00AM: Abstract Number: 1223

Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1233

Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study

9:00AM-11:00AM: Abstract Number: 1225

Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California

9:00AM-11:00AM: Abstract Number: 1221

Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards

9:00AM-11:00AM: Abstract Number: 1228

Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 1222

Suboptimal Immunization Coverage Among Rheumatology Patients in Routine Clinical Care

9:00AM-11:00AM: Abstract Number: 1218

Synovial Fluid Culture: Comparison of Two Culture Methods

9:00AM-11:00AM: Abstract Number: 1232

Synovial Fluid Profile in Neutropenic Patients with Septic Arthritis

9:00AM-11:00AM: Abstract Number: 1238

The Effect of Antibiotic Therapy on Positive Culture Results Among Patients with Prosthetic Joint Septic Arthritis

9:00AM-11:00AM: Abstract Number: 1220

The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis

9:00AM-11:00AM: Abstract Number: 1216

To Study the Frequency of Persistent Arthritis, in Patients with Chikungunya Fever, in a Tertiary Health Care Center

9:00AM-11:00AM: Abstract Number: 1217

Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy over the Last 20 Years

9:00AM-11:00AM: Abstract Number: 1237

What Is the Value of Synovial Biopsies for the Diagnosis of Septic Arthritis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].